Form 8-K - Current report:
SEC Accession No. 0001140361-25-001461
Filing Date
2025-01-21
Accepted
2025-01-21 08:11:46
Documents
15
Period of Report
2025-01-17
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K ny20040698x7_8k.htm   iXBRL 8-K 36147
2 EXHIBIT 2.1 ny20040698x7_ex2-1.htm EX-2.1 40901
3 EXHIBIT 99.1 ny20040698x7_ex99-1.htm EX-99.1 24021
  Complete submission text file 0001140361-25-001461.txt   255832

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA rvnc-20250117.xsd EX-101.SCH 3980
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE rvnc-20250117_lab.xml EX-101.LAB 21967
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rvnc-20250117_pre.xml EX-101.PRE 16043
17 EXTRACTED XBRL INSTANCE DOCUMENT ny20040698x7_8k_htm.xml XML 4227
Mailing Address 1222 DEMONBREUN STREET SUITE 2000 NASHVILLE TN 37203
Business Address 1222 DEMONBREUN STREET SUITE 2000 NASHVILLE TN 37203 6157247755
Revance Therapeutics, Inc. (Filer) CIK: 0001479290 (see all company filings)

EIN.: 770551645 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36297 | Film No.: 25540497
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)